A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects (Q35976681)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects (English)

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

1 reference

based on heuristic

inferred from title

author name string

Vlasveld LT

1

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Hekman A

2

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Vyth-Dreese FA

3

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Rankin EM

4

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Scharenberg JG

5

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Voordouw AC

6

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Sein JJ

7

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Dellemijn TA

8

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Rodenhuis S

9

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Melief CJ

10

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

language of work or name

0 references

publication date

1 September 1993

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

68

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

3

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

559-567

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968412

2 October 2017

Structure and expression of a cloned cDNA for human interleukin-2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968412

2 October 2017

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968412

2 October 2017

Expression of interleukin 2 receptors on activated human B cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968412

2 October 2017

In vivo activation of lymphocytes in melanoma patients receiving escalating doses of recombinant interleukin 2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968412

2 October 2017

Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968412

2 October 2017

Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968412

2 October 2017

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968412

2 October 2017

Phase 1 clinical trial of recombinant interleukin-2: a comparison of bolus and continuous intravenous infusion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968412

2 October 2017

A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968412

2 October 2017

Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968412

2 October 2017

Characterization of the interleukin 2 receptor beta chain using three distinct monoclonal antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968412

2 October 2017

Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968412

2 October 2017

Biology and clinical relevance of human natural killer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968412

2 October 2017

The soluble interleukin-2 receptor: biology, function, and clinical application

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968412

2 October 2017

Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968412

2 October 2017

Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968412

2 October 2017

A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968412

2 October 2017

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968412

2 October 2017

Characterization of human interleukin 2 derived from Escherichia coli

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968412

11 July 2018

In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968412

11 July 2018

Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968412

11 July 2018

Appearance and phenotypic characterization of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin 2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968412

11 July 2018

Monoclonal antibody defining a molecule possibly identical to the p75 subunit of interleukin 2 receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968412

11 July 2018

Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968412

11 July 2018

Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968412

11 July 2018

Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968412

11 July 2018

Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968412

11 July 2018

Different lymphoid cell populations produce varied levels of neopterin, β2-microglobulin and soluble IL-2 receptor when stimulated with IL-2, interferon-gamma or tumour necrosis factor-alpha

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968412

11 July 2018

Functional heterogeneity of Leu 19"bright"+ and Leu 19"dim"+ lymphokine-activated killer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968412

24 September 2018

Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968412

24 September 2018

Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens

1 reference

https://pubmed.ncbi.nlm.nih.gov/8353046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation

1 reference

https://pubmed.ncbi.nlm.nih.gov/8353046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/8353046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative studies of human FcRIII-positive and negative natural killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/8353046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential expression of the IL-2 receptor subunits, p55 and p75 on various populations of primary peripheral blood mononuclear cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/8353046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype

1 reference

https://pubmed.ncbi.nlm.nih.gov/8353046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activation and expansion of tumour-infiltrating lymphocytes by anti-CD3 and anti-CD28 monoclonal antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/8353046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytolytic potential of peripheral blood T-lymphocytes following adoptive immunotherapy with lymphokine-activated killer cells and low-dose interleukin 2

1 reference

https://pubmed.ncbi.nlm.nih.gov/8353046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The 1A4 molecule (CD27) is involved in T cell activation

1 reference

https://pubmed.ncbi.nlm.nih.gov/8353046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo production of interleukin-5, granulocyte-macrophage colony-stimulating factor, macrophages colony-stimulating factor, and interleukin-6 during intravenous administration of high-dose interleukin-2 in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/8353046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/8353046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modulation of adhesion molecules on human large granular lymphocytes by interleukin-2 in vivo and in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/8353046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum CD25 levels during interleukin-2 therapy: dose dependence and correlations with clinical toxicity and lymphocyte surface sCD25 expression

1 reference

https://pubmed.ncbi.nlm.nih.gov/8353046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Participation of the CD27 antigen in the regulation of IL-2-activated human natural killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/8353046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-2 augments natural killer cell activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/8353046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor

1 reference

https://pubmed.ncbi.nlm.nih.gov/8353046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phorbol-ester-mediated induction and augmentation of mitogenesis and interleukin-2 production in human T-cell lymphoproliferative disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/8353046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biological Activity of Recombinant Human Interleukin-2 Produced inEscherichia coli

1 reference

https://pubmed.ncbi.nlm.nih.gov/8353046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/8353046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/8353046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/8353046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen

1 reference

https://pubmed.ncbi.nlm.nih.gov/8353046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.1993.386

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35976681&oldid=2198014481"